MedTrace Logo

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.

NCT03539627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2022-10-26

No results posted yet for this study

Summary

One-center, observational, non-interventional, prospective study of the efficacy of azilsartan medoxomil in patients with arterial hypertension associated with stable ischemic heart disease and type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]

patients are to receive azilsartan medoxomil

Sponsors & Collaborators

  • Research Institute for Complex Problems of Cardiovascular Diseases, Russia

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-07
Primary Completion
2022-04-29
Completion
2022-04-29
FDA Drug
Yes

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03539627 on ClinicalTrials.gov